Aardvark Therapeutics (AARD) Cash & Current Investments (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Cash & Current Investments data on file, last reported at $120.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 56.54% year-over-year to $120.0 million; the trailing twelve-month figure through Mar 2026 stood at $120.0 million (down 56.54% YoY), and the FY2025 full-year result was $110.0 million, up 49.37% from the prior year.
• Cash & Current Investments climbed to $120.0 million in Q1 2026, from $110.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $276.1 million in Q1 2025 to a low of $73.7 million in Q4 2024.
• A 3-year average of $175.1 million and a median of $166.7 million in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments soared 49.37% in 2025 and sank 56.54% in 2026, its largest moves.
• Tracing AARD's Cash & Current Investments over 3 years: stood at $73.7 million in 2024, then soared by 49.37% to $110.0 million in 2025, then grew by 9.03% to $120.0 million in 2026.
• Business Quant data shows AARD's Cash & Current Investments at $120.0 million in Q1 2026, $110.0 million in Q4 2025, and $213.5 million in Q3 2025.